Shalby Limited — Investor Meet, 02-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Shalby's consolidated financial results for Q4 FY26 show revenue rising 9.4% YoY to INR295.5 Cr, with EBITDA up 43.1% to INR37.4 Cr. Full-year PAT saw substantial improvement due to a new tax regime. The MedTech business reported ~INR40 Cr revenue (+45% YoY), marking its second consecutive quarter of positive EBITDA, with management aiming for double-digit EBITDA and positive cash flow. The Gurugram unit is expected to reach profitability soon, supported by NABH accreditation and growth in new international markets. FY26 capex of ~INR160 Cr focused on oncology and robotics, with no significant spending planned for FY27. Management expresses confidence in sustainable growth and operational efficiency.